Vazyme(SH:688105) Xin Lang Cai Jing·2026-01-23 01:40Group 1 - The core business of the company includes research and development of functional proteins and high molecular organic materials, with a focus on biological reagents, in vitro diagnostics, and antibody drug development [2] - As of September 30, the company reported a total revenue of 952 million yuan for the period from January to September 2025, representing a year-on-year decrease of 3.40%, and a net profit attributable to shareholders of 6.6152 million yuan, down 63.57% year-on-year [2] - The company has a total of 9,447 shareholders, which is an increase of 9.90% compared to the previous period, while the average circulating shares per person decreased by 9.01% to 42,101 shares [2] Group 2 - The company has distributed a total of 731 million yuan in dividends since its A-share listing, with 611 million yuan distributed over the past three years [3] Group 3 - On January 22, the company's stock price increased by 0.70%, with a trading volume of 35.0056 million yuan [1] - The financing buy-in amount on January 22 was 1.6545 million yuan, while the financing repayment was 3.3677 million yuan, resulting in a net financing buy-in of -1.7132 million yuan [1] - The total balance of margin trading for the company as of January 22 was 123 million yuan, accounting for 1.43% of the circulating market value, which is above the 90th percentile level over the past year [1]